June 2019: Promotion of PALEXIA® SR prolonged-release tablet by Grünenthal Ltd
Published 17 July 2019
© Crown copyright 2019
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-june-2019/june-2019-promotion-of-palexia-sr-prolonged-release-tablet-by-grunenthal-ltd
The MHRA has a statutory duty to ensure that advertising of medicinal products within the UK conforms with Part 14 of the Human Medicines Regulations 2012 (“the Regulations”). The MHRA carries out a number of activities in this regard including the routine scrutiny of promotional material for medicinal products.
MHRA requested that the detail aid and leave piece along with supporting references were submitted for scrutiny.
MHRA had no objection to the promotional materials submitted and had no further comments.